Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease
Amy Y. Sato, … , Tamara Alliston, Teresita Bellido
Amy Y. Sato, … , Tamara Alliston, Teresita Bellido
Published October 15, 2024
Citation Information: JCI Insight. 2024;9(21):e182664. https://doi.org/10.1172/jci.insight.182664.
View: Text | PDF
Research Article Bone biology

Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease

  • Text
  • PDF
Abstract

Despite their beneficial actions as immunosuppressants, glucocorticoids (GC) have devastating effects on the musculoskeletal and cardiac systems, as long-term treated patients exhibit high incidence of falls, bone fractures, and cardiovascular events. Herein, we show that GC upregulate simultaneously in bone, skeletal muscle, and the heart the expression of E3 ubiquitin ligases (atrogenes), known to stimulate the proteasomal degradation of proteins. Activation of vitamin D receptor (VDR) signaling with the VDR ligands calcitriol or eldecalcitol prevented GC-induced atrogene upregulation in vivo and ex vivo in bone/muscle organ cultures and preserved tissue structure/mass and function of the 3 tissues in vivo. Direct pharmacologic inhibition of the proteasome with carfilzomib also conferred musculoskeletal protection. Genetic loss of the atrogene MuRF1-mediated protein ubiquitination in ΔRING mice afforded temporary or sustained protection from GC excess in bone or skeletal and heart muscle. We concluded that the atrogene pathway downstream of MuRF1 underlies GC action in bone, muscle, and the heart, and it can be pharmacologically or genetically targeted to confer protection against the damaging actions of GC simultaneously in the 3 tissues.

Authors

Amy Y. Sato, Meloney Cregor, Kevin McAndrews, Charles A. Schurman, Eric Schaible, Jennifer Shutter, Punit Vyas, Bhawana Adhikari, Monte S. Willis, Marjan Boerma, Tamara Alliston, Teresita Bellido

×

Figure 2

Increased VDR signaling protects the skeleton from bone loss and microarchitecture deterioration by blocking GC effects of remodeling.

Options: View larger image (or click on image) Download as PowerPoint
Increased VDR signaling protects the skeleton from bone loss and microar...
(A) BMD and (B) cancellous bone volume (BV) normalized by tissue volume (TV) and representative 3D reconstructed cancellous bone images. Scale bar: 1 mm. Cortical bone area (BA) normalized by tissue area (TA) and material density after 8 weeks of the indicated treatments: slow-release pellet implantation of either 2.1 mg/kg/d prednisolone or placebo and gavaging of 50 ng/kg/d 1,25D3, ED, or vehicle 5 times per week for 8 weeks. (C and E) Sera P1NP, OCN, and CTX levels. n = 10–12. (D) Histomorphometric quantification of bone formation rate (BFR) and mineralizing surface (MS) normalized by bone surface (BS) in longitudinal sections of lumbar vertebral L1–L3 cancellous bone. n = 5–10. (F) Osteoclast surface (Oc.S) and number (Oc.N) normalized to bone surface (BS). n = 5–8. *P < 0.05 vs. corresponding placebo treated, #P < 0.05 vs. corresponding vehicle treated, ^P < 0.05 vs. corresponding 1,25D3 treated by 2-way ANOVA, Tukey’s post hoc test, ΩP < 0.05 vs. placebo and vehicle-treated controls by 1-way ANOVA, Dunnett’s method post hoc test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts